Aprea Therapeutics, Inc.
Data quality: 83%
APRE
Nasdaq
Manufacturing
Chemicals
$0.72
▲
$0.02
(2.62%)
Mkt Cap: 8.25 M
Price
$0.72
Mkt Cap
8.25 M
Day Range
$0.67 — $0.74
52-Week Range
$0.55 — $2.22
Volume
103,832
Open $0.74
50D / 200D Avg
$0.75
4.26% below
50D / 200D Avg
$1.24
41.81% below
Quick Summary
Key Takeaways
Negative free cash flow of -12.91 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-103.58%
Below sector avg (-51.02%)
ROIC-81.10%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio5.20
Interest CoverageN/A
Valuation
PE (TTM)
-0.65
Above sector avg (-1.98)
P/B Ratio0.76
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (44 peers)
Peer Comparison
vs Manufacturing sector median (44 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.7 | -2.0 |
| P/B | 0.8 | 5.1 |
| ROE % | -103.6 | -51.0 |
| Net Margin % | — | -150.2 |
| Rev Growth 5Y % | — | 9.3 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -12.60 M |
| ROE | -103.58% | ROA | -79.67% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -12.91 M |
| ROIC | -81.10% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 5.20 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 11.26 M | Tangible Book Value | 10.91 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.65 | Forward P/E | N/A |
| P/B Ratio | 0.76 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -156.56% | ||
| Market Cap | 8.25 M | Enterprise Value | -5.47 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.93 | Revenue / Share | N/A |
| FCF / Share | -1.13 | OCF / Share | -1.13 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 102.46% |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -12.60 M | -12.96 M | -14.29 M | -112.66 M | -37.13 M |
| EPS (Diluted) | -1.93 | -2.45 | -3.95 | -68.16 | -1.74 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -13.23 M | -14.32 M | -15.47 M | — | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | 23.90 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 21,715.0 | 22,318.0 | 7,052.0 | 4,403.0 | 12,829.0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 15.93 M | 23.98 M | 22.65 M | 30.16 M | 56.82 M |
| Total Liabilities | — | — | — | 3.20 M | 7.32 M |
| Shareholders' Equity | 12.44 M | 19.31 M | 16.95 M | 25.64 M | 49.51 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 14.60 M | 22.85 M | 21.61 M | 28.79 M | 53.08 M |
| Current Assets | 15.56 M | 23.58 M | 22.52 M | 30.15 M | 56.58 M |
| Current Liabilities | 2.76 M | 3.36 M | 4.39 M | 3.20 M | 7.32 M |
{"event":"ticker_viewed","properties":{"ticker":"APRE","listing_kind":"stock","pathname":"/stocks/apre","exchange":"Nasdaq","country":"US"}}